

- (51) International Patent Classification:

A61K 31/4709 (2006.01) A61K 45/06 (2006.01)

A61K 31/635 (2006.01) A61P 35/02 (2006.01)

A61K 31/706 (2006.01)
- (21) International Application Number:

PCT/US2024/036827
- (22) International Filing Date:

03 July 2024 (03.07.2024)
- (25) Filing Language:

English
- (26) Publication Language:


English
- (30) Priority Data:

63/525,639 07 July 2023 (07.07.2023) US
- (71) Applicant: RIGEL PHARMACEUTICALS, INC.

[US/US]; 611 Gateway Boulevard, Ste. 900, South San Francisco, California 94080 (US).
- (72) Inventors: CHAO, Mwe Mwe; 611 Gateway Boulevard, Ste. 900, South San Francisco, California 94080 (US). DI-NARDO, Courtney; 611 Gateway Boulevard, Ste. 900, South San Francisco, California 94080 (US).
- (74) Agent: BRUNER, Michael J.; JONES DAY, 250 Vesey Street, New York, NY 10281-1047 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:

— with international search report (Art. 21(3))

(54) Title: TREATMENT OF ACUTE MYELOID LEUKEMIA WITH OLUTASIDENIB, VENETOCLAX AND A HYPOMETHYLATING AGENT



(57) Abstract: Provided are methods of treating a subject having a hematologic malignancy or pre-malignancy that involve administering an effective amount of olutasidenib, venetoclax, and a hypomethylating agent. In some cases, the patient has an IDH1 mutation.